HOME >> MEDICINE >> NEWS
Major ovarian cancer clinical study announced at Yale using combination drug therapy

A clinical study of ovarian cancer initiated by investigators at Yale School of Medicine will combine the anti-cancer drug phenoxodiol with docetaxel for women with recurrent ovarian cancer.

"Advanced-stage ovarian cancer is one of the most devastating forms of cancer, with half of the women diagnosed with it dying within five years," said principal investigator Thomas Rutherford, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale and a member of the Yale Cancer Center. "One of the imperatives facing doctors who treat these patients is to find ways to restore sensitivity to drugs such as taxanes once they start to lose that sensitivity."

The Phase Ib/IIa clinical study is supported by Sanofi-Aventis and Marshall Edwards, Inc. It will combine phenoxodiol, which is in the investigational phase with docetaxel, a second-generation taxane--drug that inhibits cell growth by stopping cell division--commonly used in patients with recurrent or persistent ovarian cancer that has failed other therapies, including the first generation taxane paclitaxel. The clinical response rate to any chemotherapeutic is often limited due to rapid development of chemo-resistance in women with recurrent ovarian cancer.

The purpose of the study is to determine if the addition of phenoxodiol to docetaxel can improve clinical response and survival by delaying or preventing the development of chemo-resistance in women with recurrent ovarian cancer.

The study will enroll 60 women with recurrent epithelial ovarian, fallopian tube or abdominal cavity cancer after treatment with a platinum and paclitaxel. All 60 patients will be given docetaxel by injection weekly; half the patients will also be given oral phenoxodiol daily, and the other half a placebo tablet. Tumor response will be determined on the basis of tumor burden (RECIST criteria) in patients with measurable disease, and tumor marker levels (GCIG criteria
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
28-Nov-2005


Page: 1 2

Related medicine news :

1. Chinese space agency joins the International Charter Space and Major Disasters
2. Major employers, physicians, stakeholders unite to revolutionize Americas healthcare system
3. Majority of herb users dont follow evidence-based indications, researchers find
4. Majority of state Medicaid programs have or plan to have pay-for-performance programs
5. Major discovery raises prospect of better patient care by improving platelet life span
6. Major visual disorders in people over 40 may be costing the US economy billions
7. Major cancer study aims to identify protein markers for early-stage disease
8. Majority of health care opinion leaders say Medicare Part D helps beneficiaries, changes are needed
9. Major grant to IU School of Medicine will expand HIV/AIDS programs in Kenya
10. Major WHO study concludes calcium supplements can reduce complications during pregnancy
11. Major biomarker candidates for Alzheimers disease explored

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2020)... ... March 22, 2020 , ... In times ... to be a frivolous luxury. The world’s focus is on practical matters - ... sense of stability and control in chaos. However, it’s during these times that ...
(Date:3/20/2020)... , ... March 20, 2020 , ... ... together an interdisciplinary team of researchers in machine learning, bioinformatics, immunology, virology and ... current and future outbreaks. , "The COVID-19 crisis gives us an opportunity and ...
(Date:3/19/2020)... ... 19, 2020 , ... For weeks, SignatureCare Emergency Center has been preparing its ... it announced that while we are still short of some critical safety equipment, medical ... our preparedness measures to be complete. , The Houston, TX based company said it ...
(Date:3/19/2020)... ... March 19, 2020 , ... Van Dyk Health Care, which sold ... Caring, on October 3, 2018 and is not involved in the operations of these ... Family of Caring at Montclair. , “We are devastated to learn about the recent ...
(Date:3/16/2020)... ... March 16, 2020 , ... The National Kidney ... Coronavirus SARS-CoV-2 (the virus that causes COVID-19 disease) to NKR’s vast network of ... serves approximately 100 transplant programs throughout the United States. NKR has relied on ...
Breaking Medicine News(10 mins):
(Date:3/22/2020)... ... March 21, 2020 , ... Since 1988, Gwatney dealerships have strived to ... heighten over the spread of COVID-19, Gwatney Mazda is pleased to announce two new ... of the Memphis community. , The dealership’s new Home Test Drives and Delivery ...
(Date:3/20/2020)... , ... March 20, 2020 , ... Despite the presence ... alpha-gal in Texas and the Gulf of Mexico are low, and it might be ... for the first time at the 2020 Annual Meeting of the American Academy of ...
(Date:3/20/2020)... ... March 20, 2020 , ... Today, in response to Maryland Governor Larry ... public health emergency, Mercy Medical Center sought and received an Emergency Certificate ... acute care unit on the 17th floor of the hospital’s main inpatient facility, The ...
Breaking Medicine Technology:
Cached News: